top of page

Supply Chain Management

 Small/Large Molecules and Cell & Gene Therapy products

The degree of de-centralization / localization will further increase driven primarily by the post-covid strategies (drug substance, drug product manufacturing) as well as unsustainable Cost of Goods in the Cell & Gene Therapy space.               A seamless end to end supply chain has always been the goal, and we have hoped for digitization to solve challenges the industry has been facing for a decade to ultimately convert geographically scattered, unpractical processes into digital but still inefficient supply chains. Are you ready to challenge the current operating model ?  

Get in touch with us to acquire guidance in following areas:

  • Mergers/Acquisitions/Carve-Out of Plants

    • Project Leadership, PMO​

    • Change Management

  • Manufacturing

    • De-centralization, Network Strategy

    • Business Process Mapping (patient vs. drug journey)

    • From pre-clinical to clinical: Establishing a Clinical Supply Chain from scratch

    • First time Commercialization (eg. cell & gene therapy products)

  • In-/Outsourcing

    • Supplier Due Diligence, Assessment & Selection, Onboarding, Monitoring

    • Neutral party to mitigate a potential "Man-In-Plant" situation

  • Distribution

    • Logistics lanes/shippers/network: ambient, cold chain at 2-8°C, frozen and liquid nitrogen

    • Warehousing material flows (goods-in/-out, storage)

  • Staff

    • Interim Specialists (interim managers, specialized freelancers)​

Whether tactical or strategic, clinical or commercial, we help to assess the current status and increase the Service Delivery experience.

Get in touch with us to learn more

bottom of page